Xtera Biopharma is headquartered in Lenexa, Kansas, one of the mid-west’s leading technology centers. We intend to use our licensed and proprietary Allianz™ technology to bring to market highly innovative therapeutic products that will dramatically increase the quality of patient care and reduce hospital re-admissions.

Our Allianz™ technology platform combines a biodegradable, time-released delivery system with Calcitonin Gene Related Peptide (CGRP) agonist analogs and delivers them in highly efficacious doses over time. The result will be exclusive, breakthrough formulations that mitigate the risks of such diseases as heart failure, myocardial infarction, and ischemic kidney failure. These formulations improve blood circulation, provide cardio protection and reduce inflammation of the heart muscle.

We believe that the implementation of these technologically advanced and patented treatment systems will provide products that are superior to those currently available. Xtera has valid scientific evidence to support that its first product, Cardio XT™, will provide improved blood circulation, cardio protection, reduce heart muscle inflammation, and improve heart and kidney function over time.

We are in the final stages of completing the evaluation of Allianz™ in preclinical tests for the treatment of Acute Decompensated Heart Failure. When completed, we will seek Investigational New Drug (IND) approval from the FDA for clinical evaluation in Phase I and II trials at the Cleveland Clinic. Xtera's Clinical Research Steering Committee , established in conjunction with the Cleveland Clinic, has guided our clinical process and has developed clinical protocols to evaluate the drug in human heart failure patients.